These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 22155744

  • 1. A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer.
    Lee H, Li GY, Jeong Y, Jung KH, Lee JH, Ham K, Hong S, Hong SS.
    Cancer Lett; 2012 May 01; 318(1):68-75. PubMed ID: 22155744
    [Abstract] [Full Text] [Related]

  • 2. A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.
    Li GY, Jung KH, Lee H, Son MK, Seo J, Hong SW, Jeong Y, Hong S, Hong SS.
    Cancer Lett; 2013 Feb 01; 329(1):59-67. PubMed ID: 23085493
    [Abstract] [Full Text] [Related]

  • 3. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
    Lee H, Jung KH, Jeong Y, Hong S, Hong SS.
    Cancer Lett; 2013 Jan 01; 328(1):152-9. PubMed ID: 22929971
    [Abstract] [Full Text] [Related]

  • 4. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 5. A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer.
    Yuan Q, Cai S, Zhang X, Liu Z, Li Z, Luo X, Xiong C, Wang J, Hu J, Ruan J.
    Cancer Lett; 2012 Nov 28; 324(2):210-20. PubMed ID: 22652174
    [Abstract] [Full Text] [Related]

  • 6. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
    Jung KH, Zheng HM, Jeong Y, Choi MJ, Lee H, Hong SW, Lee HS, Son MK, Lee S, Hong S, Hong SS.
    Cancer Lett; 2013 Jan 01; 328(1):176-87. PubMed ID: 22902995
    [Abstract] [Full Text] [Related]

  • 7. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X, Voi M.
    Clin Cancer Res; 2012 Aug 01; 18(15):4104-13. PubMed ID: 22693356
    [Abstract] [Full Text] [Related]

  • 8. Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells.
    Kuo PL, Chen CY, Hsu YL.
    Cancer Res; 2007 Aug 01; 67(15):7406-20. PubMed ID: 17671211
    [Abstract] [Full Text] [Related]

  • 9. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM, Jung KH, Lee H, Son MK, Seo JH, Yan HH, Park BH, Hong S, Hong SS.
    Cancer Lett; 2013 May 01; 331(2):250-61. PubMed ID: 23340175
    [Abstract] [Full Text] [Related]

  • 10. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.
    Clin Cancer Res; 2009 Jul 15; 15(14):4649-64. PubMed ID: 19567590
    [Abstract] [Full Text] [Related]

  • 11. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
    Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):830-8. PubMed ID: 20522531
    [Abstract] [Full Text] [Related]

  • 12. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
    Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, Leiter A, Karlan B, Mehta R, Koeffler HP.
    Oncogene; 2010 Jan 14; 29(2):285-96. PubMed ID: 19855437
    [Abstract] [Full Text] [Related]

  • 13. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.
    Cancer Res; 2008 Oct 01; 68(19):8022-30. PubMed ID: 18829560
    [Abstract] [Full Text] [Related]

  • 14. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
    Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K.
    Biochem Pharmacol; 2012 Mar 15; 83(6):723-32. PubMed ID: 22209867
    [Abstract] [Full Text] [Related]

  • 15. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
    Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H, Maruta H.
    Cancer Lett; 2007 Jan 08; 245(1-2):242-51. PubMed ID: 16540233
    [Abstract] [Full Text] [Related]

  • 16. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
    Kim SJ, Jung KH, Son MK, Park JH, Yan HH, Fang Z, Kang YW, Han B, Lim JH, Hong SS.
    Cancer Lett; 2017 Sep 10; 403():339-353. PubMed ID: 28688971
    [Abstract] [Full Text] [Related]

  • 17. Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo.
    Hseu YC, Chen SC, Chen HC, Liao JW, Yang HL.
    Food Chem Toxicol; 2008 Aug 10; 46(8):2680-8. PubMed ID: 18550246
    [Abstract] [Full Text] [Related]

  • 18. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.
    Cancer Chemother Pharmacol; 2010 Nov 10; 66(6):1131-40. PubMed ID: 20838997
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner.
    Liu ZB, Hou YF, Zhu J, Hu DL, Jin W, Ou ZL, Di GH, Wu J, Shen ZZ, Shao ZM.
    Oncogene; 2010 May 20; 29(20):2996-3009. PubMed ID: 20228837
    [Abstract] [Full Text] [Related]

  • 20. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.
    Chen J, Zeng J, Xin M, Huang W, Chen X.
    Horm Metab Res; 2011 Sep 20; 43(10):681-6. PubMed ID: 21932171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.